NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today posted an overview of new data on BMS-790052 on the company website, available here. BMS-790052 is an NS5A inhibitor in Phase 2 development for the treatment of hepatitis C. The data were presented today at the European Association for the Study of the Liver (EASL) meeting in Vienna.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com.
Bristol-Myers Squibb CompanyMedia:Sonia Choi, 609-252-5132sonia.choi@bms.comorInvestors:John Elicker, 609-252-4611john.elicker@bms.com